FDA Narcolepsy Breakthrough: Takeda’s oral orexin agonist oveporexton (Orzeyful) won FDA approval for narcolepsy type 1 in adults, with RMAT designation also highlighted for Aspen Neuroscience’s sasineprocel. Cancer & Cell Therapy Debate: New discussion questions whether CAR T outcomes are shaped by patient selection, and how that affects evidence for earlier use in multiple myeloma. GLP-1 Cardiovascular Data: Database-backed findings suggest tirzepatide initiation in type 2 diabetes with ASCVD may lower major adverse cardiovascular events versus placebo proxy. Healthcare Access & Costs: A report on the ACA claims fraud drove enrollment drops, while critics point to higher premiums and deductibles leaving millions uninsured. Mental Health Services: UK mental health charities warn Northern Ireland’s strategy remains underfunded despite new UK crisis-service investment. Public Health Equity: WHO-linked analysis estimates heavy hepatitis B mother-to-child transmission in Africa and calls for higher birth-dose vaccination plus maternal antivirals. Rural Care Pressure: A commentary argues kidney value-based care hasn’t reduced hospital spending, and that the cost-driving hospitalization happens earlier than targets. Patient Safety in Practice: A study finds standard clinic schedules can push working patients out of outpatient alcohol recovery. Industry Watch: RadNet posted record quarterly revenue and guidance updates, while Depo-Provera litigation continues to grow over alleged safety warnings.